Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects.
D001519:Behavior / Q000502:physiology; D001679:Biogenic Amines / Q000502:physiology*; D003010:Clorgyline / Q000494:pharmacology; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D004298:Dopamine / Q000502:physiology; D006632:Histamine / Q000502:physiology; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009638:Norepinephrine / Q000502:physiology; D010293:Pargyline / Q000494:pharmacology; D010627:Phenethylamines / Q000502:physiology; D012642:Selegiline / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology; D014439:Tyramine / Q000502:physiology
D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D012642:Selegiline; C029261:phenethylamine; D012701:Serotonin; D006632:Histamine; D010293:Pargyline; D003010:Clorgyline; D004298:Dopamine; D009638:Norepinephrine; D014439:Tyramine